TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02147964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: Acyline 300 ug/kg SQ injections every 2-weeks for 4 months \[all subjects\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: Acyline 300 ug/kg SQ injections every 2-weeks for 4 months \[all subjects\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: Acyline 300 ug/kg SQ injections every 2-weeks for 4 months \[all subjects\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: Acyline 300 ug/kg SQ injections every 2-weeks for 4 months \[all subjects\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: Dutasteride 2.5 mg (day 1) followed by 0.5 mg daily for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: ketoconazole 400 mg PO daily for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: ketoconazole 400 mg PO daily for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG
Description: HCG 60 IU injection Subcutaneously, every other day for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo dutasteride
Description: placebo oral dutasteride PO daily for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo dutasteride
Description: placebo oral dutasteride PO daily for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo ketoconazole
Description: placebo ketoconazole daily for 4 months
Study: NCT03008759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dentifrice 100% Nano-F
Description: Use of few of dentifrice 100% Nanoencapsulated Fluoride on brushing for one week, twice day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dentifrice 100% Nano-F
Description: Use of few of dentifrice 100% Nanoencapsulated Fluoride on brushing for one week, twice day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dentifrice 50% Nano-F
Description: Use of few of dentifrice 50% Nanoencapsulated Fluoride on brushing for one week, twice day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dentifrice 50% Nano-F
Description: Use of few of dentifrice 50% Nanoencapsulated Fluoride on brushing for one week, twice day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dentifrice standard
Description: Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluorid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dentifrice standard
Description: Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluorid
Study: NCT02170909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS high dose
Study: NCT03051594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fluorescent camera
Description: used too detect residual caries depending on the bacterial byproducts.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: caries detector dye
Description: dye used to detect the residual caries.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: visual tactile assessment
Description: method usually used to detect the residual caries.
Study: NCT01831817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice
Description: Calcium sodium phosphosilicate dentifrice (5% w/w) and 1500 ppm F as sodium monofluorophosphate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice
Description: No calcium sodium phosphosilicate and 1500 ppm F as sodium monofluorophosphate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monofluorophosphate dentifrice
Description: Sodium monofluorophospate dentifrice (1000 ppm F)
Study: NCT05798598

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scientific writing training course
Description: Attendance to a training course on scientific writing. Attendees learn about the importance of scientific writing, structure and writing an original paper, how scientific publishing works, as well as how to interact with journal editors and reviewers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scientific writing training course
Description: Attendance to a training course on scientific writing. Attendees learn about the importance of scientific writing, structure and writing an original paper, how scientific publishing works, as well as how to interact with journal editors and reviewers.
Study: NCT01831817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride dentifrice
Description: Dentifrice containing 1100ppm F as sodium fluoride
Study: NCT00428207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart versus Insulin Lispro
Description: Subjects will be randomly assigned to insulin aspart versus insulin lispro via random number generation. Half of the patients will begin with insulin aspart, and then will be crossed over to insulin lispro. The insulin sequence will be reversed for the other half of the patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro versus Insulin Aspart
Description: Subjects will be randomly assigned to insulin lispro versus insulin aspart via random number generation. Half of the patients will begin with insulin lispro, and then will be crossed over to insulin aspart. The insulin sequence will be reversed for the other half of the patients.
Study: NCT00946673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Orally up to 400 mg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Single fraction stereotactic radiotherapy - Standard of Care
Study: NCT01294163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: Inhaled xenon, maximal inspired concentration of 65%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Inhaled sevoflurane, maximal inspired concentration of 1.8%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Hourly dose of 2-4 mg/kg
Study: NCT05749120

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Recipient vessel selected for microanastomosis
Description: Free tissue flaps harvesting and microanastomosis were performed by the same surgeon and in a similar way in both group. Postoperative course, and complications were recorded and analyzed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recipient vessel selected for microanastomosis
Description: Free tissue flaps harvesting and microanastomosis were performed by the same surgeon and in a similar way in both group. Postoperative course, and complications were recorded and analyzed.
Study: NCT05011799

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cancer Educational Materials
Description: Receive prostate cancer educational materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend peer-led education sessions
Study: NCT02737384

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depletion in CD45RA graft donor
Description: Experimental treatment: negative fraction after CD34+ selection from PBSC graft is depleted of naïve CD45RA+ cells. this fraction is reinjected to the recipient and is the experimental product.~Conditioning regimen:~Up-front ATG from D-14 toD-11 Busulphan IV from D-8 to -5 Fludarabine from D-7 to D-4 Thiothepa D-3 to D-2~Graft: CD34+ cells positively selected cells from PBSC of the donor~Post transplant immunosuppression: ciclosporin started at D-1 to D+100
Study: NCT04665531

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Catheter
Description: Patients in the experimental group will receive the Erector Spinae Catheter with an initial bolus ob 20ml 0,5% levobupivacaine prior the surgery and will be administered local anesthetics for 48 hours post-operatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal block
Description: Patients in the comparative group will receive standard treatment, i.e. the multi-level intercostal block with 20ml 0,5% levobupivacaine administered at the end of the surgery by the surgeon.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% Injectable Solution
Description: Patients in the experimental group will receive Ropivacaine 0,2% continous infusion of 5ml/h with boluses 15ml/4h by the Erector Spinae Catheter for 48 hours post-operatively.
Study: NCT02155530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg
Description: homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pravastatin 20 mg
Description: Intervention description : homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
Study: NCT00712582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide, carboplatin, ifosfamide
Description: Patients in consolidation A will receive three drugs in a regimen called ICE. You will have 3 cycles. Each new cycle begins 2 to 3 weeks after the last one.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Ifosfamide, Etoposide, Carboplatin
Description: It consists of four drugs in a regimen called augmented RICE (augRICE). It is given every 3 weeks for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine
Description: It consists of four drugs in a regimen called augRICE. It is given every 3 weeks for 2 cycles. After the rituximab on day 3, you will then be admitted to the hospital for 2 to 3 nights.~Part 2: Stem Cell Collection, Part 3: High dose chemoradiotherapy and stem cell transplant. Your doctor may want you to get radiation therapy. If so, it will start 2 weeks before the highdose chemotherapy. This regimen is called CBV-N chemotherapy. It is given by vein in the hospital.
Study: NCT01326832

Intervention type: DEVICE
Intervention: Primoris
Description: Total hip arthroplasty with the new Primoris femoral component
Study: NCT03491995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Classic treatment
Description: Omeprazole, amoxycillin, clarithromycin
Study: NCT04349488

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Anodal Transcranial Direct Current Stimulation
Description: Subjects received a micro-current through their scalp to induce cortical and subcortical changes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal Transcranial Direct Current Stimulation
Description: Subjects received a micro-current through their scalp to induce cortical and subcortical changes
Study: NCT00536107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250 mg oral

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT or MRI
Description: performed at screening and every 6 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT or MRI
Description: performed at screening and every 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 60mg/m2 intravenous infusion
Study: NCT02047357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Learning Through Play Plus
Description: Learning Through Play (LTP) Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
Study: NCT02420691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO
Study: NCT04390477

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Oral daily capsule containing probiotic strains with maltodextrin as excipient, administrated for 30 days.
Study: NCT03797209

Intervention type: DEVICE
Intervention: EUS-guided fistulization AXIOS
Description: By using a convex type ultrasonic endoscope to form a fistula by gastrointestinal puncture, to perform various drainage.
Study: NCT00870896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Each subject will then receive Spiriva 18 ug/day for a total of 4 weeks. Each subject will be instructed by the PI on the proper use of the Spiriva inhaler and demonstrate the ability to properly perform the inhalation technique prior to leaving the laboratory. The patient will receive their first dose in the laboratory under the direct supervision of one of the investigators. In addition, subjects will be requested to take their Spiriva inhalation treatment the same time each day.
Study: NCT04140526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC-392
Description: ONC-392 will be given by intravenous infusion, once every 21 days (Q3W). In Part C Arm M and in Part D, ONC-392 will be given Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC-392
Description: ONC-392 will be given by intravenous infusion, once every 21 days (Q3W). In Part C Arm M and in Part D, ONC-392 will be given Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC-392
Description: ONC-392 will be given by intravenous infusion, once every 21 days (Q3W). In Part C Arm M and in Part D, ONC-392 will be given Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be given intravenous (IV) infusion at 200 mg/cycle, once every 21 days (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be given intravenous (IV) infusion at 75 mg/m2, once every 21 days (Q3W).
Study: NCT06418919

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation treatment
Description: RFA is used to ablate the entire thyroid gland
Study: NCT04584736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Livalo, Ezetrol
Description: Pitavastatin+Ezetimibe Pitavastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livalo, Ezetrol
Description: Pitavastatin+Ezetimibe Pitavastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Livalo, Ezetrol
Description: Pitavastatin+Ezetimibe Pitavastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livalo, Ezetrol
Description: Pitavastatin+Ezetimibe Pitavastatin
Study: NCT02447601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168
Description: 200µg,injected subcutaneously,once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40mg,oral,two times
Study: NCT02771288

Intervention type: DEVICE
Group type: OTHER
Intervention: Bioresorbable Vascular Scaffold
Study: NCT03655314

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NEWT
Description: The Newborn Weight Tool (NEWT) is publicly available at www.newbornweight.org. For this intervention, NEWT will be embedded into the electronic medical record along with a flag for weight loss greater than or equal to the 75th centile of birth weight.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: The electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight.
Study: NCT01107197

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enriched nutrition formula
Description: oral formula enriched in arginine, zinc and antioxidant oligoelements

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control formula
Description: Isonitrogenous isocaloric oral formula
Study: NCT02246114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: piCO+ Smokerlyzer® monitor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text messages
Study: NCT03636347

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: twice daily administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alvelestat oral tablet - dose 1
Description: twice daily administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alvelestat oral tablet - dose 2
Description: twice daily administration
Study: NCT05880927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Patients receive pyrotinib 400mg/day for half or one year
Study: NCT00721734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib was administered intravenously (IV) at a rate of approximately 10 mL/minute.
Study: NCT04098224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smART+ System
Description: Utilizing the smART+ System to provide feeding optimization to the patient
Study: NCT02749643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile feedback system
Study: NCT00761267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Description: Day 1: loading dose of 3 mg/kg (not to exceed 200 mg) Day 2 onwards: maintain a dose of 1.5 mg/kg (not to exceed 100 mg). Minimum total treatment duration is 14 days. Minimum IV anidulafungin treatment duration is 10 days for subjects with microbiologically confirmed ICC and 5 days for subjects at risk of candidiasis; followed by oral fluconazole 6-12 mg/kg/day (not to exceed 800mg/day).~Maximum treatment duration with anidulafungin is 35 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Subjects may be switched to oral fluconazole \[6-12 mg/kg/day (not to exceed 800mg/day\] provided they meet specified criteria. Maximum total treatment duration is 49 days.
Study: NCT03150758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10Hz + 100 micro-seconds
Description: 10Hz Electrical Stimulation with a pulse width of 100 micro-seconds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10Hz + 200 micro-seconds
Description: 10Hz Electrical Stimulation with a pulse width of 200 micro-seconds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7Hz + 100 micro-seconds
Description: 7Hz Electrical Stimulation with a pulse width of 100 micro-seconds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7Hz + 200 micro-seconds
Description: 7Hz Electrical Stimulation with a pulse width of 200 micro-seconds
Study: NCT02696200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q Collar
Description: The device is fitted to the neck to provide a comfortable and precise jugular compression that potentially mitigates cerebral slosh. The device will be worn inside the collar of an athletic compression shirt.
Study: NCT06032689

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Xtra-fill
Description: the material was placed in bulk.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: x-base
Description: The x-base liner was placed and then veneered with Xtra-fill.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Admira fusion x-tra
Description: bulk placement of the restoration Admira fusion -xtra.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Admira fusion x-base
Description: Admira fusion x-base liner was used and then veneered by Admira fusion x-tra.
Study: NCT02733484

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the patients in this arm will receive placebo intervention
Study: NCT02601859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Study: NCT03676504

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19.CAR T Cells
Description: Dose Level 1: 1×10\^6 transduced cells/m\^2; Dose Level 2: 5×10\^6 transduced cells/m\^2; Dose Level 3: 20×10\^6 transduced cells/m\^2; Dose Level 4: 5x10\^7 transduced cells/m\^2; Dose Level 5: 10x10\^7 transduced cells/m\^2; Dose Level 6: 20x10\^7 transduced cells/m\^2
Study: NCT02708771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids omega-3
Description: 4 daily capsules of polyunsaturated fatty acids omega-3, during 4 weeks. Each capsule contains: 460 mg eicosapentaenoic acid ethyl ester and 380 mg docosahexaenoic acid ethyl ester.
Study: NCT03676504

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19.CAR T Cells
Description: Dose Level 1: 1×10\^6 transduced cells/m\^2; Dose Level 2: 5×10\^6 transduced cells/m\^2; Dose Level 3: 20×10\^6 transduced cells/m\^2; Dose Level 4: 5x10\^7 transduced cells/m\^2; Dose Level 5: 10x10\^7 transduced cells/m\^2; Dose Level 6: 20x10\^7 transduced cells/m\^2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19.CAR T Cells
Description: Dose Level 1: 1×10\^6 transduced cells/m\^2; Dose Level 2: 5×10\^6 transduced cells/m\^2; Dose Level 3: 20×10\^6 transduced cells/m\^2; Dose Level 4: 5x10\^7 transduced cells/m\^2; Dose Level 5: 10x10\^7 transduced cells/m\^2; Dose Level 6: 20x10\^7 transduced cells/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 3 days of fludarabine 30 mg/m\^2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 3 days of fludarabine 30 mg/m\^2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 3 days of fludarabine 30 mg/m\^2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 3 days of cyclophosphamide 500 mg/m\^2/day
Study: NCT00115895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radioactive iodine
Description: Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq

Intervention type: DRUG
Group type: OTHER
Intervention: Radioactive iodine
Description: Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq